Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8092832 | CEPHALON | Generally linear effervescent oral fentanyl dosage form and methods of administering |
Dec, 2024
(1 year, 11 months from now) | |
US8119158 | CEPHALON | Effervescent oral fentanyl dosage form and methods of administering fentanyl |
Dec, 2024
(1 year, 11 months from now) | |
US7862833 | CEPHALON | Effervescent oral opiate dosage forms and methods of administering opiates |
Jun, 2028
(5 years from now) | |
US7862832 | CEPHALON | Generally linear effervescent oral fentanyl dosage form and methods of administering |
Jun, 2028
(5 years from now) |
Drugs and Companies using FENTANYL CITRATE ingredient
Market Authorisation Date: 25 September, 2006
Treatment: NA
Dosage: TABLET;BUCCAL, SUBLINGUAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US7132570 | CEPHALON | Method for the production of crystalline forms and crystalline forms of optical enantiomers of modafinil |
Dec, 2023
(10 months from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7297346 | CEPHALON | Pharmaceutical formulations of modafinil |
Nov, 2023
(10 months from now) | |
US7297346
(Pediatric) | CEPHALON | Pharmaceutical formulations of modafinil |
May, 2024
(1 year, 4 months from now) | |
US7132570
(Pediatric) | CEPHALON | Method for the production of crystalline forms and crystalline forms of optical enantiomers of modafinil |
Jun, 2024
(1 year, 4 months from now) |
Drugs and Companies using ARMODAFINIL ingredient
Market Authorisation Date: 15 June, 2007
Treatment: NA
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7297346 | CEPHALON | Pharmaceutical formulations of modafinil |
Nov, 2023
(10 months from now) | |
US7297346
(Pediatric) | CEPHALON | Pharmaceutical formulations of modafinil |
May, 2024
(1 year, 4 months from now) |
Drugs and Companies using MODAFINIL ingredient
Market Authorisation Date: 24 December, 1998
Treatment: NA
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8445524 | CEPHALON | Solid forms of bendamustine hydrochloride |
Mar, 2029
(6 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8895756 | CEPHALON | Bendamustine pharmaceutical compositions |
Jan, 2026
(2 years from now) | |
US8609863 | CEPHALON | Bendamustine pharmaceutical compositions |
Jan, 2026
(2 years from now) | |
US8791270 | CEPHALON | Bendamustine pharmaceutical compositions |
Jan, 2026
(2 years from now) | |
US8609863
(Pediatric) | CEPHALON | Bendamustine pharmaceutical compositions |
Jul, 2026
(3 years from now) | |
US8791270
(Pediatric) | CEPHALON | Bendamustine pharmaceutical compositions |
Jul, 2026
(3 years from now) | |
US8895756
(Pediatric) | CEPHALON | Bendamustine pharmaceutical compositions |
Jul, 2026
(3 years from now) | |
US8883836 | CEPHALON | Solid forms of bendamustine hydrochloride |
Mar, 2029
(6 years from now) | |
US9533955 | CEPHALON | Solid forms of bendamustine hydrochloride |
Mar, 2029
(6 years from now) | |
US8669279 | CEPHALON | Solid forms of bendamustine hydrochloride |
Mar, 2029
(6 years from now) | |
US8344006 | CEPHALON | Liquid formulations of bendamustine |
Sep, 2029
(6 years from now) | |
US8445524
(Pediatric) | CEPHALON | Solid forms of bendamustine hydrochloride |
Sep, 2029
(6 years from now) | |
US8883836
(Pediatric) | CEPHALON | Solid forms of bendamustine hydrochloride |
Sep, 2029
(6 years from now) | |
US8669279
(Pediatric) | CEPHALON | Solid forms of bendamustine hydrochloride |
Sep, 2029
(6 years from now) | |
US8344006
(Pediatric) | CEPHALON | Liquid formulations of bendamustine |
Mar, 2030
(7 years from now) | |
US8436190 | CEPHALON | Bendamustine pharmaceutical compositions |
Oct, 2030
(7 years from now) | |
US8436190
(Pediatric) | CEPHALON | Bendamustine pharmaceutical compositions |
Apr, 2031
(8 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Dec 7, 2022 |
Drugs and Companies using BENDAMUSTINE HYDROCHLORIDE ingredient
Market Authorisation Date: 20 March, 2008
Treatment: For use in the treatment of patients with chronic lymphocytic leukemia and/or non-hodgkins lymphoma; For use in the treatment of patients with chronic lymphocytic leukemia (cll) and/or indolent b-cell non-hodgkin lymphoma (nhl); For use in the treatment of patients with indolent b-cell non-hodgkin lymphoma; For use in the treatment of patients with chronic lymphocytic leukemia (cll)
Dosage: POWDER;IV (INFUSION); SOLUTION;IV (INFUSION)
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic